JP5363726B2 - グレリン受容体の大環状モジュレーターの使用方法 - Google Patents
グレリン受容体の大環状モジュレーターの使用方法 Download PDFInfo
- Publication number
- JP5363726B2 JP5363726B2 JP2007516620A JP2007516620A JP5363726B2 JP 5363726 B2 JP5363726 B2 JP 5363726B2 JP 2007516620 A JP2007516620 A JP 2007516620A JP 2007516620 A JP2007516620 A JP 2007516620A JP 5363726 B2 JP5363726 B2 JP 5363726B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- ring
- compound
- ghrelin
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(cc1)c(*)cc1N Chemical compound *c(cc1)c(*)cc1N 0.000 description 4
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/872,142 | 2004-06-18 | ||
US10/872,142 US7521420B2 (en) | 2003-06-18 | 2004-06-18 | Macrocyclic antagonists of the motilin receptor |
US62164204P | 2004-10-26 | 2004-10-26 | |
US60/621,642 | 2004-10-26 | ||
US62200504P | 2004-10-27 | 2004-10-27 | |
US60/622,055 | 2004-10-27 | ||
US64227105P | 2005-01-07 | 2005-01-07 | |
US60/642,271 | 2005-01-07 | ||
US11/149,731 | 2005-06-10 | ||
US11/149,731 US7476653B2 (en) | 2003-06-18 | 2005-06-10 | Macrocyclic modulators of the ghrelin receptor |
PCT/US2005/020857 WO2006009674A1 (en) | 2004-06-18 | 2005-06-13 | Macrocyclic modulators of the ghrelin receptor |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011177778A Division JP5739766B2 (ja) | 2004-06-18 | 2011-08-15 | グレリン受容体の大環状モジュレーターの使用方法 |
JP2012219493A Division JP5730835B2 (ja) | 2004-06-18 | 2012-10-01 | グレリン受容体の大環状モジュレーターの使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008504238A JP2008504238A (ja) | 2008-02-14 |
JP5363726B2 true JP5363726B2 (ja) | 2013-12-11 |
Family
ID=35427667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007516620A Expired - Fee Related JP5363726B2 (ja) | 2004-06-18 | 2005-06-13 | グレリン受容体の大環状モジュレーターの使用方法 |
Country Status (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012006961A (ja) * | 2004-06-18 | 2012-01-12 | Tranzyme Pharma Inc | グレリン受容体の大環状モジュレーターの使用方法 |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
JP4928261B2 (ja) * | 2003-06-18 | 2012-05-09 | トランザイム・ファーマ・インコーポレイテッド | モチリン受容体の大環状拮抗薬 |
US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
US8921521B2 (en) * | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
US7550431B2 (en) * | 2003-07-31 | 2009-06-23 | Tranzyme Pharma Inc. | Spatially-defined macrocycles incorporating peptide bond surrogates |
AU2004261329B2 (en) * | 2003-07-31 | 2011-10-27 | Ocera Therapeutics, Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
JP5730835B2 (ja) * | 2004-06-18 | 2015-06-10 | オセラ セラピューティクス, インコーポレイテッド | グレリン受容体の大環状モジュレーターの使用方法 |
US20090275648A1 (en) * | 2005-06-13 | 2009-11-05 | Fraser Graeme L | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
EP1891090A2 (en) * | 2005-06-13 | 2008-02-27 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
HUE044391T2 (hu) | 2005-09-29 | 2019-10-28 | Ipsen Pharma | Készítmény gasztrointesztinális motilitászavar kezelésére |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
WO2007106385A2 (en) * | 2006-03-10 | 2007-09-20 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
EP2431380A3 (en) | 2006-09-11 | 2013-07-03 | Tranzyme Pharma, Inc. | Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
US20100216706A1 (en) * | 2007-05-15 | 2010-08-26 | Horvath Tamas L | Ghrelin Protects Substantia Nigra Dopamine Neurons |
CN101951937A (zh) * | 2007-12-21 | 2011-01-19 | 赫尔辛医疗股份公司 | 使用伊帕瑞林刺激胃肠系统动力的方法 |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
EP2483407A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
MX2012003912A (es) * | 2009-09-30 | 2012-08-17 | Tranzyme Pharma Inc | Sales, solvatos y composiciones farmaceuticas de los agonistas macrociclicos del receptor de ghrelina y metodos para su uso. |
EP2491004A4 (en) * | 2009-10-23 | 2013-07-03 | Tranzyme Pharma Inc | MACROCYCLIC INHIBITORS OF SERINE PROTEASE CYMS |
JP2013509434A (ja) | 2009-10-30 | 2013-03-14 | トランザイム・ファーマ,インコーポレイテッド | 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法 |
US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011146845A1 (en) * | 2010-05-21 | 2011-11-24 | Tranzyme Pharma, Inc. | Modified macrocyclic ghrelin receptor modulators and methods of using the same |
EP2582715B1 (en) * | 2010-06-16 | 2018-11-28 | The Administrators of the Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
WO2012016186A1 (en) * | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
KR20180058866A (ko) | 2010-08-13 | 2018-06-01 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
WO2013006451A2 (en) | 2011-07-01 | 2013-01-10 | President And Fellows Of Harvard College | Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof |
BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
CN102557989B (zh) * | 2011-12-19 | 2013-12-25 | 深圳翰宇药业股份有限公司 | 优利莫瑞林中间体以及优利莫瑞林制备方法 |
US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
US8927500B2 (en) | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
CN105072909A (zh) * | 2012-09-27 | 2015-11-18 | 阿莱塔纳治疗学股份有限公司 | 应用控制食欲不振的化合物的组合物和方法 |
RU2655811C2 (ru) | 2012-10-24 | 2018-05-29 | Дайити Санкио Компани, Лимитед | Терапевтическое средство для бокового амиотрофического склероза |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
CN103864588B (zh) * | 2014-03-25 | 2015-09-09 | 河北工业大学 | 一种2,3-二甲氧基苯甲醛的制备方法 |
JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
MX2017006205A (es) | 2014-11-12 | 2017-11-17 | Lyric Pharmaceuticals Inc | Tratamiento de la intoleracia a la alimentacion enteral. |
ES2902795T3 (es) | 2015-01-28 | 2022-03-29 | Elanco Animal Health Incorporated | Composición para uso crónico como compuesto para aumentar de peso |
US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US11040976B2 (en) | 2015-04-24 | 2021-06-22 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof |
PT3368544T (pt) | 2015-10-27 | 2020-08-20 | Hoffmann La Roche | Péptidos macrocíclicos contra acinetobacter baumannii |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
EP3388444A1 (en) | 2017-04-10 | 2018-10-17 | F. Hoffmann-La Roche AG | Anti-bacterial peptide macrocycles and use thereof |
CN107759660A (zh) * | 2017-12-05 | 2018-03-06 | 陕西慧康生物科技有限责任公司 | 一种三肽‑29的液‑固相合成方法 |
US11674136B2 (en) | 2018-02-09 | 2023-06-13 | President And Fellows Of Harvard College | DNA-templated macrocycle library |
US11505573B2 (en) | 2018-03-28 | 2022-11-22 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
NZ188418A (en) | 1977-10-03 | 1981-02-11 | Mobil Oil Corp | Lubricants containing oil and an oxazoline |
WO1989007110A1 (en) | 1988-01-28 | 1989-08-10 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
DK0554381T3 (da) | 1990-10-25 | 1996-04-09 | Genentech Inc | Anvendelse af beskyttende midler mod reaktive oxygenforbindelser |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
US5726319A (en) | 1992-11-06 | 1998-03-10 | Merck & Co., Inc. | Biphenyl substituted dipeptide analogs promote release of growth hormone |
WO1994011012A1 (en) | 1992-11-06 | 1994-05-26 | Merck & Co., Inc. | Substituted dipeptide analogs promote release of growth hormone |
US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
CZ151495A3 (en) | 1992-12-11 | 1995-12-13 | Merck & Co Inc | Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof |
PL314003A1 (en) | 1993-10-19 | 1996-08-05 | Merck & Co Inc | Combination of bisulphonates and substances enhancing secretion of growth hormone |
SK56296A3 (en) | 1993-11-09 | 1997-02-05 | Merck & Co Inc | Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them |
US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
EP0730578A4 (en) | 1993-11-24 | 1997-10-08 | Merck & Co Inc | COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES |
US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
EP0736038B1 (en) | 1993-12-23 | 2001-07-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
EP0736039B1 (en) | 1993-12-23 | 2000-10-25 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
WO1996002530A1 (en) | 1994-07-20 | 1996-02-01 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
AU4495996A (en) | 1995-01-25 | 1996-08-14 | Nippon Chemiphar Co. Ltd. | Dihydrophenazine derivatives |
UA55381C2 (uk) | 1995-01-27 | 2003-04-15 | Ново Нордіск А/С | Похідні пептиду (варіанти), що здатні вивільнювати гормон росту, фармацевтична композиція (варіанти), спосіб стимулювання вивільнення гормону росту з гіпофіза, способи підвищення швидкості і темпу росту та виробництва молока або вовни, спосіб лікування нездужань |
WO1996024587A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1996024580A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5559128A (en) | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
WO1996033189A1 (en) | 1995-04-19 | 1996-10-24 | Merck & Co., Inc. | Process for the preparation of spiroindolines |
WO1996035713A1 (en) | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
US5936089A (en) | 1995-05-29 | 1999-08-10 | Pfizer Inc | Dipeptides which promote release of growth hormone |
BR9608909A (pt) | 1995-06-22 | 1999-03-02 | Novo Nordisk As | Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto |
ZA966891B (en) | 1995-08-21 | 1998-02-16 | Lilly Co Eli | 2-acylaminopropanamines as growth hormone secretagogues. |
WO1997006803A1 (en) | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997011697A1 (en) | 1995-09-26 | 1997-04-03 | Merck & Co., Inc. | 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone |
US5723616A (en) | 1995-10-27 | 1998-03-03 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
WO1997015191A1 (en) | 1995-10-27 | 1997-05-01 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
HUP9902095A3 (en) | 1995-10-27 | 2001-05-28 | Merck & Co Inc | New process for the preparation of a growth hormone secretagogue |
US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
DE69636394T2 (de) | 1995-12-13 | 2007-07-19 | Merck & Co., Inc. | Testverfahren für die sekretionsrezeptoren von wachstumshormonen |
CA2240427C (en) | 1995-12-13 | 2007-08-14 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
WO1997022367A1 (en) | 1995-12-20 | 1997-06-26 | Merck & Co., Inc. | Radiolabeled growth hormone secretagogue |
IT1277113B1 (it) | 1995-12-20 | 1997-11-04 | Romano Deghenghi | Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita |
AU715856B2 (en) | 1995-12-22 | 2000-02-10 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
WO1997034604A1 (en) | 1996-03-21 | 1997-09-25 | Merck & Co., Inc. | 4-spiroindoline piperidines promote release of growth hormone |
AU2722297A (en) | 1996-04-03 | 1997-10-22 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
SE9601397D0 (sv) | 1996-04-12 | 1996-04-12 | Pharmacia Ab | Use of growth hormone |
AU2382097A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
AU722421B2 (en) | 1996-04-24 | 2000-08-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5919777A (en) | 1996-04-24 | 1999-07-06 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1997041878A1 (en) | 1996-05-07 | 1997-11-13 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
EP0900086A4 (en) | 1996-05-07 | 2000-01-12 | Merck & Co Inc | IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES |
AU2764797A (en) | 1996-05-14 | 1997-12-05 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
AU3220097A (en) | 1996-05-22 | 1997-12-09 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
IL126983A0 (en) | 1996-05-31 | 1999-09-22 | Novo Nordisk As | Growth hormone components and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis |
WO1998003473A1 (en) | 1996-07-22 | 1998-01-29 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
WO1998018815A1 (en) | 1996-10-25 | 1998-05-07 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
SE9703929D0 (sv) | 1996-11-22 | 1997-10-28 | Pharmacia & Upjohn Ab | Therapeutical use and method |
WO1998046569A1 (fr) | 1997-04-11 | 1998-10-22 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de benzene |
JP2000514838A (ja) | 1997-05-14 | 2000-11-07 | 藤沢薬品工業株式会社 | 成長ホルモンの放出を促進するピペリジノ誘導体 |
WO1998058950A1 (en) | 1997-06-20 | 1998-12-30 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
US6251902B1 (en) | 1997-06-25 | 2001-06-26 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
US6864250B1 (en) | 1997-08-22 | 2005-03-08 | Kaken Pharmaceutical Co., Ltd. | N-acylated lipophilic amino acid derivatives |
US6737407B1 (en) | 1997-09-08 | 2004-05-18 | Metabolic Pharmaceuticals, Ltd. | Treatment of obesity |
IL137007A0 (en) | 1998-01-16 | 2001-06-14 | Novo Nordisk As | Compounds with growth hormone releasing properties |
WO1999039730A1 (fr) | 1998-02-09 | 1999-08-12 | Kaken Pharmaceutical Co., Ltd. | Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance |
HUP0100998A3 (en) | 1998-03-03 | 2001-12-28 | Novo Nordisk As | (2e)-5-amino-5-methylhex-2-enoic acid n-methyl-n-((1r)-1-(n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphtyl)ethyl)amide salts, methods for their preparation, pharmaceutical compositions comprising thereof and their use |
MA26618A1 (fr) * | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
IL139090A0 (en) | 1998-05-11 | 2001-11-25 | Novo Nordisk As | Compounds with growth hormone releasing properties |
WO1999064456A1 (en) | 1998-06-09 | 1999-12-16 | Novo Nordisk A/S | A method for preparing a compound with growth hormone releasing properties |
PA8475901A1 (es) | 1998-06-16 | 2000-05-24 | Pfizer Prod Inc | Terapia de combinacion para la fragilidad musculoesqueletica |
AU3342099A (en) | 1998-06-16 | 2000-01-05 | Pfizer Products Inc. | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
KR100907638B1 (ko) | 1998-06-30 | 2009-07-14 | 노보 노르디스크 에이/에스 | 성장 호르몬 방출성을 가지는 화합물 |
DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
EP1112282A4 (en) | 1998-08-10 | 2002-10-31 | Merck & Co Inc | RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG |
ATE288895T1 (de) | 1998-08-20 | 2005-02-15 | Sumitomo Pharma | Wachstumshormon-freisetzende oxindolderivate |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
CA2343214A1 (en) * | 1998-09-03 | 2000-03-16 | Chris Edward Williams | Neuroprotection |
JP2003503055A (ja) | 1999-06-30 | 2003-01-28 | ザイモジェネティクス,インコーポレイティド | Sgipペプチド |
CA2284459C (en) | 1999-10-04 | 2012-12-11 | Neokimia Inc. | Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
WO2001047558A1 (fr) | 1999-12-28 | 2001-07-05 | Kaken Pharmaceutical Co., Ltd. | Medicaments protegeant les nerfs |
CN1935833A (zh) * | 2000-04-19 | 2007-03-28 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
WO2001092292A2 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Ghrelin analogs |
DE60140285D1 (de) * | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
HU229233B1 (en) | 2000-06-13 | 2013-09-30 | Aeterna Zentaris Gmbh | Growth hormone secretagogues |
WO2001097831A1 (fr) | 2000-06-23 | 2001-12-27 | Kaken Pharmaceutical Co., Ltd. | Agents therapeutiques et prophylactiques destines a l'insuffisance cardiaque |
US6576686B1 (en) | 2000-06-27 | 2003-06-10 | Exxonmobil Chemical Patents Inc. | Road marking compound comprising linear tetrablock copolymers |
US6635784B2 (en) * | 2000-09-29 | 2003-10-21 | Eastman Chemical Company | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates |
AU2002250081A1 (en) | 2001-02-14 | 2002-08-28 | Uab Research Foundation | Combined transductional and transcriptional targeting system for improved gene delivery |
ITMI20011445A1 (it) | 2001-07-06 | 2003-01-06 | Europ Geie | Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita |
JPWO2004014412A1 (ja) | 2002-08-09 | 2005-12-02 | 科研製薬株式会社 | 心筋細胞保護剤 |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
JP4928261B2 (ja) * | 2003-06-18 | 2012-05-09 | トランザイム・ファーマ・インコーポレイテッド | モチリン受容体の大環状拮抗薬 |
US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
AU2004261329B2 (en) | 2003-07-31 | 2011-10-27 | Ocera Therapeutics, Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
US7550431B2 (en) | 2003-07-31 | 2009-06-23 | Tranzyme Pharma Inc. | Spatially-defined macrocycles incorporating peptide bond surrogates |
BRPI0807046A2 (pt) * | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
MX2012003912A (es) | 2009-09-30 | 2012-08-17 | Tranzyme Pharma Inc | Sales, solvatos y composiciones farmaceuticas de los agonistas macrociclicos del receptor de ghrelina y metodos para su uso. |
-
2005
- 2005-06-10 US US11/149,731 patent/US7476653B2/en not_active Ceased
- 2005-06-13 EP EP11009050.3A patent/EP2457893B1/en active Active
- 2005-06-13 CA CA2579726A patent/CA2579726C/en not_active Expired - Fee Related
- 2005-06-13 CN CN2005800280726A patent/CN101111512B/zh not_active Expired - Fee Related
- 2005-06-13 ES ES05785185T patent/ES2393498T3/es active Active
- 2005-06-13 WO PCT/US2005/020857 patent/WO2006009674A1/en active Application Filing
- 2005-06-13 EP EP05785185A patent/EP1773869B9/en not_active Not-in-force
- 2005-06-13 EP EP11009051A patent/EP2457925A1/en not_active Withdrawn
- 2005-06-13 JP JP2007516620A patent/JP5363726B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,395 patent/US8334256B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012006961A (ja) * | 2004-06-18 | 2012-01-12 | Tranzyme Pharma Inc | グレリン受容体の大環状モジュレーターの使用方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060025566A1 (en) | 2006-02-02 |
US8334256B2 (en) | 2012-12-18 |
CA2579726A1 (en) | 2006-01-26 |
WO2006009674A8 (en) | 2009-11-26 |
EP1773869B9 (en) | 2013-01-23 |
CN101111512A (zh) | 2008-01-23 |
ES2393498T3 (es) | 2012-12-21 |
EP1773869B1 (en) | 2012-08-22 |
EP2457893A1 (en) | 2012-05-30 |
US20090221689A1 (en) | 2009-09-03 |
WO2006009674A1 (en) | 2006-01-26 |
EP1773869A1 (en) | 2007-04-18 |
EP2457893B1 (en) | 2017-08-16 |
US7476653B2 (en) | 2009-01-13 |
CN101111512B (zh) | 2013-05-01 |
JP2008504238A (ja) | 2008-02-14 |
EP2457925A1 (en) | 2012-05-30 |
CA2579726C (en) | 2015-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5363726B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
JP5219509B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
EP2644618B1 (en) | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators | |
USRE42013E1 (en) | Macrocyclic modulators of the ghrelin receptor | |
USRE42624E1 (en) | Methods of using macrocyclic modulators of the ghrelin receptor | |
US20090198050A1 (en) | Macrocyclic Modulators of the Ghrelin Receptor | |
JP5739766B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
JP5730835B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
US9493505B2 (en) | Macrocyclic modulators of the ghrelin receptor | |
US20180110824A1 (en) | Macrocyclic Modulators of the Ghrelin Receptor | |
ES2646887T3 (es) | Compuestos intermedios para moduladores macrocíclicos del receptor de ghrelina | |
AU2015201862B2 (en) | Macrocyclic ghrelin receptor modulators and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110516 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110523 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110815 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20120330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120629 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120730 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120830 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120906 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121001 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130208 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130508 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130821 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130827 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130906 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5363726 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |